CN103720740A - Gynostemma pentaphylla extract and fungus transformation preparation method thereof - Google Patents
Gynostemma pentaphylla extract and fungus transformation preparation method thereof Download PDFInfo
- Publication number
- CN103720740A CN103720740A CN201410019158.3A CN201410019158A CN103720740A CN 103720740 A CN103720740 A CN 103720740A CN 201410019158 A CN201410019158 A CN 201410019158A CN 103720740 A CN103720740 A CN 103720740A
- Authority
- CN
- China
- Prior art keywords
- extract
- gynostemma
- gynostemma pentaphyllum
- ethanol
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 title claims abstract description 66
- 239000000284 extract Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 241001065361 Gynostemma Species 0.000 title claims abstract 12
- 241000233866 Fungi Species 0.000 title claims description 6
- 230000009466 transformation Effects 0.000 title abstract description 7
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract description 58
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000000855 fermentation Methods 0.000 claims abstract description 12
- 230000004151 fermentation Effects 0.000 claims abstract description 12
- 241000223261 Trichoderma viride Species 0.000 claims abstract description 10
- 241000235389 Absidia Species 0.000 claims abstract description 9
- 241000228245 Aspergillus niger Species 0.000 claims abstract description 9
- 239000001963 growth medium Substances 0.000 claims abstract description 9
- 238000004362 fungal culture Methods 0.000 claims abstract description 7
- 230000002829 reductive effect Effects 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 6
- 230000000813 microbial effect Effects 0.000 claims abstract 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 229930187479 gypenoside Natural products 0.000 claims description 5
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229930183991 damulin Natural products 0.000 claims 2
- 238000000605 extraction Methods 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 230000002538 fungal effect Effects 0.000 abstract description 4
- LTJZMSTVPKBWKB-HGZKDYFJSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(2r,3r,5r,8r,9r,10r,12r,13r,14r,17s)-2,12-dihydroxy-17-[(2s)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-dihydroxy-6 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)C[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LTJZMSTVPKBWKB-HGZKDYFJSA-N 0.000 description 20
- LTJZMSTVPKBWKB-XUYZQZLKSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(2r,3r,5r,8r,9r,10r,12r,13r,14r,17s)-2,12-dihydroxy-17-[(2r)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-dihydroxy-6 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)C[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LTJZMSTVPKBWKB-XUYZQZLKSA-N 0.000 description 11
- LTJZMSTVPKBWKB-UHFFFAOYSA-N gypenoside LI Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CC(O)C4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O LTJZMSTVPKBWKB-UHFFFAOYSA-N 0.000 description 11
- 229930182490 saponin Natural products 0.000 description 6
- 235000017709 saponins Nutrition 0.000 description 6
- YHVZKDRAJHNHJX-UDBICBSZSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(2r,3r,5r,8r,9r,10r,12r,13r,14r,17s)-2,12-dihydroxy-4,4,8,10,14-pentamethyl-17-(6-methylhepta-1,5-dien-2-yl)-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-dihydroxy-6-(hydroxym Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)C[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4C(=C)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YHVZKDRAJHNHJX-UDBICBSZSA-N 0.000 description 5
- BMSPHMYCTYOUPF-SNVBIOCGSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(2r,3r,5r,8r,9r,10r,12r,13r,14r,17s)-2,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2e)-6-methylhepta-2,5-dien-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-dihydroxy-6-(hyd Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)C[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4C(/C)=C/CC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O BMSPHMYCTYOUPF-SNVBIOCGSA-N 0.000 description 5
- 239000012675 alcoholic extract Substances 0.000 description 5
- BMSPHMYCTYOUPF-HYIBBFQISA-N damulin A Natural products CC(=CCC=C(C)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(C)(C)[C@H]4CC[C@@]23C)C BMSPHMYCTYOUPF-HYIBBFQISA-N 0.000 description 5
- YHVZKDRAJHNHJX-UHFFFAOYSA-N damulin B Natural products CC(C)=CCCC(=C)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CC(O)C4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O YHVZKDRAJHNHJX-UHFFFAOYSA-N 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 241000208340 Araliaceae Species 0.000 description 4
- 241000219104 Cucurbitaceae Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 241000044446 Melinis Species 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- 241000223259 Trichoderma Species 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- -1 exist in Araliaceae Natural products 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229930002600 steroidal saponin Natural products 0.000 description 2
- 229930182493 triterpene saponin Natural products 0.000 description 2
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical class O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- 241000258957 Asteroidea Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000234272 Dioscoreaceae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- 241000251511 Holothuroidea Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241000208977 Polygalaceae Species 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明涉及一种绞股蓝提取物及其真菌转化制备方法,该提取物的制备方法是:取绞股蓝乙醇提取物,在绿色木霉、分枝犁头霉和黑曲霉真菌培养基27-30℃条件进行发酵1-6天,将发酵后的绞股蓝总提物冷冻干燥,用8-10倍量(v/w,mL/g)的80%乙醇超声提取2-4次,每次20-40min。将发酵绞股蓝乙醇提取液减压浓缩,干燥得到本发明所述的绞股蓝提取物。通过采用微生物转化的方法制备的绞股蓝提取物中活性成分的含量明显提高。The invention relates to a Gynostemma Gynostemma extract and a preparation method for fungal transformation thereof. The preparation method of the extract is as follows: take the Gynostemma pentaphyllum ethanol extract, and put it on the fungal culture medium of Trichoderma viride, Absidia cladoides and Aspergillus niger at 27-30°C Fermentation is carried out for 1-6 days, the total fermented Gynostemma pentaphyllum extract is freeze-dried, and ultrasonically extracted with 80% ethanol of 8-10 times the amount (v/w, mL/g) for 2-4 times, each time for 20-40 min. The fermented Gynostemma pentaphyllum ethanol extract is concentrated under reduced pressure and dried to obtain the Gynostemma pentaphyllum extract of the present invention. The content of active ingredients in the Gynostemma pentaphyllum extract prepared by adopting the method of microbial transformation is obviously increased.
Description
技术领域technical field
本发明涉及一种富含达木林A、达木林B、gypenoside L和gypenoside LI的绞股蓝(Gynostemmapentaphyllum)提取物,以及该提取物的真菌转化制备方法。The invention relates to a Gynostemma pentaphyllum extract rich in damulin A, damulin B, gypenoside L and gypenoside LI, and a method for preparing the extract through fungal transformation.
背景技术Background technique
皂苷类化合物是以C30骨架作为母核的糖苷,广泛存在于植物界中。根据碳骨架不同可分为三萜皂苷和甾体皂苷[1]。其中,三萜皂苷主要存在于五加科、豆科、远志科和葫芦科,甾体皂苷主要存在于薯蓣科、百合科和玄参科。此外,海星、海参等海洋生物中也存在皂苷类化合物。皂苷类成分具有复杂的物理化学性质(如具有发泡和乳化作用),因而也具有广泛的药理活性,如抗肿瘤、抗炎、抗微生物、抗糖尿病、抗氧化、免疫促进以及心血管和神经保护等作用[2-7]。Saponins are glycosides with a C30 skeleton as the core, and are widely found in the plant kingdom. According to different carbon skeletons, they can be divided into triterpene saponins and steroidal saponins [1]. Among them, triterpene saponins mainly exist in Araliaceae, Fabaceae, Polygalaceae and Cucurbitaceae, and steroidal saponins mainly exist in Dioscoreaceae, Liliaceae and Scrophulariaceae. In addition, saponins also exist in marine organisms such as starfish and sea cucumbers. Saponins have complex physicochemical properties (such as foaming and emulsifying effects), and thus also have a wide range of pharmacological activities, such as anti-tumor, anti-inflammatory, anti-microbial, anti-diabetic, anti-oxidation, immune promotion, and cardiovascular and neurological Protection and other functions [2-7].
皂苷具有许多不同的生物活性,如人参皂苷Rb1在C3和C20位均连有糖基,具有保护神经[8]、改善记忆作用[9]。而人参皂苷Rg3和Rh2,它们只在C3位连有糖基,具有较强的抗肿瘤活性[10,11]。前期研究表明,热处理绞股蓝产物中分离得到的绞股蓝皂苷gypenosideL、gypenoside LI、damulin A和damulin B具有较强的抑制非小细胞肺癌增殖作用[12]。但这四个化合物在绞股蓝原植物中含量甚微。因此,对于这些含量低的皂苷类活性成分的合理转化和结构修饰已成为当今药物研究的一个热点。Saponins have many different biological activities. For example, ginsenoside Rb1 has sugar groups at C3 and C20, which can protect nerves [8] and improve memory [9]. Ginsenosides Rg3 and Rh2, which only have sugar groups at the C3 position, have strong antitumor activity [10,11]. Previous studies have shown that the gypenosides gypenoside L, gypenoside LI, damulin A and damulin B isolated from heat-treated Gynostemma pentaphyllum products have a strong inhibitory effect on the proliferation of non-small cell lung cancer [12]. But the content of these four compounds in Gynostemma pentaphyllum is very small. Therefore, the rational transformation and structural modification of these low-content saponin active ingredients has become a hot spot in current pharmaceutical research.
绞股蓝为葫芦科(Cucurbitaceae)绞股蓝属(Gynostemma)绞股蓝Gynostemmapentaphyllum(Thunb.)Makino的全草[13],具有清热解毒,止咳祛痰等功能。由于绞股蓝中含有与人参相似的达玛烷类皂苷,又被冠予“南方人参”、“第二人参”的美誉[14]。Gynostemma pentaphyllum is the whole herb of Gynostemma pentaphyllum (Thunb.) Makino in Cucurbitaceae (Cucurbitaceae) Gynostemma Gynostemma pentaphyllum (Thunb.) Makino [13]. Because Gynostemma pentaphyllum contains dammarane saponins similar to ginseng, it has been dubbed "Southern ginseng" and "Second ginseng" [14].
利用微生物对有机化合物进行生物转化是获得化学合成方法难以得到的新类型结构的有效方法之一,微生物对三萜类化合物的区域选择性和立体选择性转化已被广泛研究[15,16]。参考文献:The biotransformation of organic compounds by microorganisms is one of the effective methods to obtain new types of structures that are difficult to obtain by chemical synthesis methods. The regioselective and stereoselective transformations of triterpenoids by microorganisms have been extensively studied [15,16]. references:
[1]Vincken J P,Heng L,de Groot A,et al.Saponins,classification and℃currence in the plantkingdom[J].Phyt℃hemistry,2007,68(3):275-297.[1] Vincken J P, Heng L, de Groot A, et al. Saponins, classification and °Currence in the plant kingdom[J]. Phyt °Chemistry, 2007, 68(3): 275-297.
[2]Petronelli A,Pannitteri G,Testa U.Triterpenoids as new promising anticancer drugs[J].Anticancer Drugs,2009,20(10):880-892.[2] Petronelli A, Pannitteri G, Testa U. Triterpenoids as new promising anticancer drugs [J]. Anticancer Drugs, 2009, 20(10): 880-892.
[3]Shin E M,Zhou H Y,Xu G H,et al.Anti-inflammatory activity of hispidol A25-methyl ether,a triterpenoid isolated from Ponciri Immaturus Fructus[J].Eur.J.Pharmacol,2010,627(1-3):318-324.[3]Shin E M, Zhou H Y, Xu G H, et al.Anti-inflammatory activity of hispidol A25-methyl ether, a triterpenoid isolated from Ponciri Immaturus Fructus[J].Eur.J.Pharmacol, 2010, 627( 1-3): 318-324.
[4]Yodsaoue O,Sonprasit J,Karalai C,et al.Diterpenoids and triterpenoids with potentialanti-inflammatory activity from the leaves of Aglaia odorata[J].Phyt℃hemistry,2012,76:83-91.[4] Yodsaoue O, Sonprasit J, Karalai C, et al. Diterpenoids and triterpenoids with potentialanti-inflammatory activity from the leaves of Aglaia odorata[J]. Phyt ° chemistry, 2012, 76: 83-91.
[5]Yadava R N,JharbadeJ.A new bioactive triterpenoid saponin from the seeds of Lactucascariola Linn[J].Nat.Prod.Res,2007,21(6):500-506.[5] Yadava R N, Jharbade J. A new bioactive triterpenoid saponin from the seeds of Lactucascariola Linn [J]. Nat. Prod. Res, 2007, 21(6): 500-506.
[6]Yoon S H,Han E J,Sung J H,et al.Anti-diabetic effects of compound K versus metforminversus compound K-metformin combination therapy in diabetic db/db mice[J].Biol.Pharm.Bull,2007,30(11):2196-2200.[6]Yoon S H, Han E J, Sung J H, et al.Anti-diabetic effects of compound K versus metforminversus compound K-metformin combination therapy in diabetic db/db mice[J].Biol.Pharm.Bull, 2007 , 30(11): 2196-2200.
[7]Kim Y A,Kong C S,Lee J I,et al.Evaluation of novel antioxidant triterpenoid saponins fromthe halophyte Salicornia herbacea[J].Bioorg.Med.Chem.Lett,2012,22(13):4318-4322.[7]Kim Y A, Kong C S, Lee J I, et al.Evaluation of novel antioxidant triterpenoid saponins from the halophyte Salicornia herbacea[J].Bioorg.Med.Chem.Lett,2012,22(13):4318-4322 .
[8]刘忞,张均田.人参皂甙Rb1和Rg1对原代培养大鼠海马神经细胞的保护作用[J].药学学报,1995,30(9):674-678.[8] Liu Min, Zhang Juntian. Protective effects of ginsenosides Rb1 and Rg1 on primary cultured rat hippocampal neurons [J]. Acta Pharmaceutica Sinica, 1995, 30(9): 674-678.
[9]Wang Q,Sun L H,Jia W,et al.Comparison of ginsenosides Rg1and Rb1for their effects onimproving scopolamine-induced learning and memory impairment in mice[J].Phytother.Res,2010,24(12):1748-1754.[9] Wang Q, Sun L H, Jia W, et al. Comparison of ginsenosides Rg1 and Rb1 for their effects on improving scopolamine-induced learning and memory impairment in mice[J]. Phytother. Res, 2010, 24(12): 1748- 1754.
[10]Jiang J W,Chen X M,Chen X H,et al.Ginsenoside Rg3inhibit hepat℃ellular carcinomagrowth via intrinsic apoptotic pathway[J].World J.Gastroenterol,2011,17(31):3605-3613.[10] Jiang J W, Chen X M, Chen X H, et al.Ginsenoside Rg3inhibit hepat°cellular carcinoma growth via intrinsic apoptotic pathway[J].World J.Gastroenterol, 2011, 17(31): 3605-3613.
[11]Li B,Zhao J,Wang C Z,et al.Ginsenoside Rh2induces apoptosis and paraptosis-like celldeath in colorectal cancer cells through activation of p53[J].Cancer Lett,2011,301(2):185-192.[11] Li B, Zhao J, Wang C Z, et al. Ginsenoside Rh2induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53[J]. Cancer Lett, 2011, 301(2): 185-192.
[12]Piao X L,Wu Q,Yang J,et al.Dammarane-type saponins from heat-pr℃essed Gynostemmapentaphyllum show fortified activity against A549cells[J].Arch Pharn Res,2013,36(7):874-879.[12]Piao X L, Wu Q, Yang J, et al.Dammarane-type saponins from heat-pr Cessed Gynostemmapentaphyllum show fortified activity against A549cells[J].Arch Pharn Res, 2013, 36(7): 874-879 .
[13]梁启成,钟鸣,中国状药学[M],广西民族出版社,2005.[13] Liang Qicheng, Zhong Ming, Chinese Pharmacology [M], Guangxi Minzu Publishing House, 2005.
[14]张涛,袁弟顺.中国绞股蓝种质资源研究进展[J].云南农业大学学报,2009,24(3):459-469.[14] Zhang Tao, Yuan Dishun. Research progress on germplasm resources of Gynostemma pentaphyllum in China [J]. Journal of Yunnan Agricultural University, 2009, 24(3): 459-469.
[15]Huang F X,Yang W Z,Ye F,et al.Microbial trahsformation of ursolic acid bySyncephalastrum racemosum(Cohn)Schroter AS3.264[J].Phyt℃hemistry,2012,82:56-60.[15] Huang F X, Yang W Z, Ye F, et al. Microbial trauma of ursolic acid by Syncephalastrum racemosum (Cohn) Schroter AS3.264 [J]. Phyt ° chemistry, 2012, 82: 56-60.
[16]Dong A,Ye M,Guo H,et al.Microbial transformation of ginsenoside Rb1by Rhizopusstolonifer and Curvularia lunata[J].Biotechnol.Lett,2003,25(4):339-344.[16] Dong A, Ye M, Guo H, et al. Microbial transformation of ginsenoside Rb1by Rhizopusstlonifer and Curvularia lunata[J]. Biotechnol. Lett, 2003, 25(4): 339-344.
发明内容Contents of the invention
本发明的目的在于提出一种富含达木林A(damulin A)、达木林B(damulin B)、gypenosideL和gypenoside LI的绞股蓝提取物,该提取物的制备方法,以及该提取物在制备治疗肿瘤药物中的用途。通过采用真菌转化的方法制备的绞股蓝提取物中抗肿瘤活性成分的含量明显提高,进而增强了本发明的绞股蓝提取物治疗肿瘤的效果。The object of the present invention is to propose a kind of Jiaogulan extract rich in damulin A (damulin A), damulin B (damulin B), gypenoside L and gypenoside LI, the preparation method of the extract, and the use of the extract in preparing and treating tumors Uses in medicine. The content of anti-tumor active components in the Gynostemma pentaphyllum extract prepared by adopting the fungal transformation method is obviously increased, thereby enhancing the effect of the Gynostemma pentaphyllum extract of the present invention on treating tumors.
本发明的绞股蓝提取物中含有以下化合物:The Gynostemma pentaphyllum extract of the present invention contains the following compounds:
本发明的绞股蓝提取物的制备方法如下:The preparation method of Gynostemma pentaphyllum extract of the present invention is as follows:
取绞股蓝乙醇提取物,在真菌培养基27-31℃条件进行发酵1-10天,将发酵后的绞股蓝总提物用等体积正丁醇萃取1-6次,减压浓缩,干燥得到本发明所述的绞股蓝提取物,所述的真菌选自绿色木霉、分枝犁头霉和黑曲霉。Take the ethanol extract of Gynostemma pentaphyllum, ferment it for 1-10 days in the fungal culture medium at 27-31°C, extract the total fermented Gynostemma pentaphyllum extract with an equal volume of n-butanol for 1-6 times, concentrate under reduced pressure, and dry to obtain the present invention. For the Gynostemma pentaphyllum extract, the fungus is selected from Trichoderma viride, Absidia cladoides and Aspergillus niger.
优选的制备方法如下:The preferred preparation method is as follows:
取绞股蓝乙醇提取物,在真菌培养基28-30℃条件进行发酵2-8天,将发酵后的绞股蓝总提物用等体积正丁醇萃取2-4次,减压浓缩,干燥得到本发明所述的绞股蓝提取物,所述的真菌选自绿色木霉、分枝犁头霉和黑曲霉。Take the ethanol extract of Gynostemma pentaphyllum, ferment it for 2-8 days under the condition of 28-30°C in the fungal culture medium, extract the total fermented Gynostemma pentaphyllum extract with an equal volume of n-butanol for 2-4 times, concentrate under reduced pressure, and dry to obtain the present invention For the Gynostemma pentaphyllum extract, the fungus is selected from Trichoderma viride, Absidia cladoides and Aspergillus niger.
进一步优选的制备方法如下:A further preferred preparation method is as follows:
取绞股蓝乙醇提取物,在真菌培养基28℃条件进行发酵7天,将发酵后的绞股蓝总提物用等体积正丁醇萃取3次,减压浓缩,干燥得到本发明所述的绞股蓝提取物,所述的真菌选自绿色木霉、分枝犁头霉和黑曲霉。Take the ethanol extract of Gynostemma pentaphyllum, ferment it for 7 days under the condition of 28°C in the fungal culture medium, extract the total Gynostemma pentaphyllum extract after fermentation with an equal volume of n-butanol for 3 times, concentrate under reduced pressure, and dry to obtain the Gynostemma pentaphyllum extract of the present invention , the fungi are selected from Trichoderma viride, Absidia cladoides and Aspergillus niger.
所述的绞股蓝乙醇提取物的制备方法为:取绞股蓝用5-10倍量(v/w,mL/g)的60-95%乙醇回流提取1-8次,每次1-5h,浓缩即得;The preparation method of the ethanol extract of Gynostemma pentaphyllum is as follows: take Gynostemma pentaphyllum and use 5-10 times the amount (v/w, mL/g) of 60-95% ethanol to reflux extract for 1-8 times, each time for 1-5h, and concentrate have to;
进一步优选:取绞股蓝用8倍量(v/w,mL/g)的80%乙醇回流提取3次,每次2h,浓缩即得。More preferably: Gynostemma pentaphyllum is extracted with 8 times the amount (v/w, mL/g) of 80% ethanol under reflux for 3 times, each time for 2 hours, and then concentrated.
本发明通过运用LCMS-IT-TOF技术手段,根据文献,鉴定了所制备的绞股蓝提取物中的4个有效成分:达木林A(damulin A)、达木林B(damulin B)、gypenoside L和gypenosideLI。并利用HPLC-MS分析方法,对该提取物中的各有效成分进行了含量变化分析。其中:The present invention identifies 4 active ingredients in the prepared Gynostemma pentaphylla extract according to the literature by using LCMS-IT-TOF technical means: Damulin A (damulin A), Damulin B (damulin B), gypenoside L and gypenoside LI . And using the HPLC-MS analysis method, the content change analysis of each active ingredient in the extract was carried out. in:
所述的化合物通过绿色木霉、分枝犁头霉和黑曲霉真菌发酵,含量均提高。The compound is fermented by Trichoderma viride, Absidia cladoides and Aspergillus niger, and the content of the compound is all increased.
所述绞股蓝提取物中有效成分的分离及鉴定如下:The separation and identification of active ingredients in the Gynostemma pentaphyllum extract are as follows:
用硅胶柱色谱方法,洗脱液二氯甲烷-甲醇的比例从10∶1至6∶1洗脱。With silica gel column chromatography, the eluent was eluted in a dichloromethane-methanol ratio from 10:1 to 6:1.
上述二氯甲烷-甲醇(6∶1)洗脱液通过LCMS-IT-TOF技术手段,根据文献,最终被鉴定为绞股蓝皂苷gypenosdie L、gypenoside LI、达木林A、达木林B。The above methylene chloride-methanol (6:1) eluate was finally identified as gypenoside gypenosdie L, gypenoside LI, Damulin A, and Damulin B through LCMS-IT-TOF technical means and according to the literature.
由于达木林A、达木林B、gypenoside L、gypenoside LI对于肺癌、胃癌、卵巢癌、乳腺癌和白血病细胞均具有较强的抑制作用,因此在本发明中,我们还提供了本发明制备得到的绞股蓝提取物在制备治疗肿瘤药物中的用途。Since Damulin A, Damulin B, gypenoside L, and gypenoside LI all have strong inhibitory effects on lung cancer, gastric cancer, ovarian cancer, breast cancer and leukemia cells, so in the present invention, we also provide the prepared Use of Jiaogulan extract in preparing medicines for treating tumors.
具体实施方式Detailed ways
实施例1提取物的制备实验Preparation experiment of embodiment 1 extract
我们比较了几种不同的制备方法制备得到的提取物,并测定了其中达木林A、达木林B、gypenoside L、gypenoside LI四个化合物的含量。结果如下:We compared the extracts prepared by several different preparation methods, and determined the content of four compounds, Damulin A, Damulin B, gypenoside L, and gypenoside LI. The result is as follows:
1.发酵前绞股蓝醇提物的制备1. Preparation of Gynostemma pentaphylla alcoholic extract before fermentation
取绞股蓝用8倍量(v/w,mL/g)的80%乙醇回流提取3次,每次2h,浓缩,得到绞股蓝乙醇提取物;在绿色木霉培养基中,直接冷冻干燥,得到发酵前绞股蓝醇提物。Take Gynostemma pentaphyllum and use 8 times the amount (v/w, mL/g) of 80% ethanol to reflux extract 3 times, each time for 2 hours, concentrate to obtain Gynostemma pentaphyllum ethanol extract; directly freeze-dry in Trichoderma viride culture medium to obtain fermented Alcoholic extract of Gynostemma pentaphyllum.
2.绞股蓝醇提物的绿色木霉、分枝犁头霉和黑曲霉真菌发酵产物的制备(本发明制备的绞股2. the preparation of Trichoderma viride, Absidia cladoides and Aspergillus niger fungal fermentation product of Gynostemma pentaphyllum ethanol extract (Gynostemma pentaphyllum prepared by the present invention 蓝提取物)blue extract)
取绞股蓝用8倍量(v/w,mL/g)的80%乙醇回流提取3次,每次2h,浓缩,得到绞股蓝乙醇提取物,在绿色木霉、分枝犁头霉和黑曲霉真菌培养基中,29℃发酵7天,冷冻干燥得到绞股蓝醇提物的发酵产物。Take Gynostemma pentaphyllum and use 8 times the amount (v/w, mL/g) of 80% ethanol to reflux extract 3 times, each time for 2h, concentrate to obtain Gynostemma pentaphyllum ethanol extract, which can be used in Trichoderma viride, Absidia cladoides and Aspergillus niger fungi In the culture medium, ferment at 29 DEG C for 7 days, and freeze-dry to obtain the fermentation product of the alcoholic extract of Gynostemma pentaphyllum.
表1不同提取物中达木林A、达木林B、gypenoside L、gypenoside LI的峰面积变化Table 1 The peak area changes of Damulin A, Damulin B, gypenoside L, and gypenoside LI in different extracts
利用HPLC-MS分析方法,对发酵前绞股蓝醇提物和绞股蓝醇提物的发酵产物进行含量比较。Using the HPLC-MS analysis method, the content of the alcoholic extract of Gynostemma pentaphyllum before fermentation and the fermentation product of Gynostemma pentaphyllum alcoholic extract were compared.
结果表明,如表1所示,本发明保护的技术方案得到的绞股蓝醇提物的发酵产物(本发明制备的绞股蓝提取物)中绞股蓝皂苷达木林A、达木林B、gypenoside L、gypenoside LI的含量提高。具体而言,雅致小克银汉霉、长枝木霉和梅林青霉转化效果较差,其中经雅致小克银汉霉转化后达木林A、达木林B、gypenoside L、gypenoside LI含量均降低;而长枝木霉和梅林青霉发酵后均未检测到四中活性成分。The results show that, as shown in Table 1, in the fermentation product of the Gynostemma pentaphyllum ethanol extract obtained by the technical scheme protected by the present invention (the Gynostemma pentaphyllum extract prepared by the present invention), the content of Gypenoside Damulin A, Damulin B, gypenoside L, and gypenoside LI content increased. Specifically, the transformation effects of C. elegans, Trichoderma longibrachiae, and Penicillium melini were poor, and the contents of Damulin A, Damulin B, gypenoside L, and gypenoside LI all decreased after being transformed by Elegantia xiaograms; while None of the four active ingredients were detected after fermentation by Trichoderma longibrachiae and Penicillium melini.
反之,绿色木霉能够使gypenoside L和gypenoside LI含量增加,而分枝犁头霉和黑曲霉能够使四种有效成分的含量均得到显著的提高。On the contrary, Trichoderma viride can increase the content of gypenoside L and gypenoside LI, while Absidia cladoides and Aspergillus niger can significantly increase the content of the four active ingredients.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410019158.3A CN103720740A (en) | 2014-01-16 | 2014-01-16 | Gynostemma pentaphylla extract and fungus transformation preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410019158.3A CN103720740A (en) | 2014-01-16 | 2014-01-16 | Gynostemma pentaphylla extract and fungus transformation preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103720740A true CN103720740A (en) | 2014-04-16 |
Family
ID=50445202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410019158.3A Pending CN103720740A (en) | 2014-01-16 | 2014-01-16 | Gynostemma pentaphylla extract and fungus transformation preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103720740A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108179169A (en) * | 2018-03-23 | 2018-06-19 | 娄志春 | A kind of method that microbe transformation method prepares damulin A |
WO2019178980A1 (en) * | 2018-03-23 | 2019-09-26 | 娄志春 | Method for preparing gynostemma pentaphylla makino saponin lvi, xlvi, l, li, damulin a or damulin b |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102603849A (en) * | 2012-02-10 | 2012-07-25 | 厦门华侨亚热带植物引种园 | Gynostemma pentaphylla secondary saponin, preparation method and applications thereof |
CN103169725A (en) * | 2013-01-29 | 2013-06-26 | 中央民族大学 | Gynostemma pentaphyllum extract and application thereof in preparation of medicament for treating tumor |
-
2014
- 2014-01-16 CN CN201410019158.3A patent/CN103720740A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102603849A (en) * | 2012-02-10 | 2012-07-25 | 厦门华侨亚热带植物引种园 | Gynostemma pentaphylla secondary saponin, preparation method and applications thereof |
CN103169725A (en) * | 2013-01-29 | 2013-06-26 | 中央民族大学 | Gynostemma pentaphyllum extract and application thereof in preparation of medicament for treating tumor |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108179169A (en) * | 2018-03-23 | 2018-06-19 | 娄志春 | A kind of method that microbe transformation method prepares damulin A |
CN108179169B (en) * | 2018-03-23 | 2018-11-23 | 江苏天芳健康科技有限公司 | A kind of method that microbe transformation method prepares damulin A |
WO2019178980A1 (en) * | 2018-03-23 | 2019-09-26 | 娄志春 | Method for preparing gynostemma pentaphylla makino saponin lvi, xlvi, l, li, damulin a or damulin b |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jin et al. | Effect of white, red and black ginseng on physicochemical properties and ginsenosides | |
CN103223018B (en) | Flos Osmanthi Fragrantis polyphenol extract and its production and use | |
CN103169725A (en) | Gynostemma pentaphyllum extract and application thereof in preparation of medicament for treating tumor | |
CN104825500A (en) | Ganoderma leucocontextum extract, extracting method thereof and application thereof | |
CN103908486A (en) | Preparing method of gynostemma pentaphyllum extraction product rich in gypenosides | |
CN102247420A (en) | Preparation method and application of eclipta extract | |
CN108003214A (en) | A kind of saponin compound and its methods and applications extracted from the rhizoma bolbostemmae | |
CN104788406B (en) | Shaggy-fruited dittany phenolic acid B and preparation method thereof and the purposes of shaggy-fruited dittany phenolic acid B | |
CN102293789A (en) | Method for extracting triterpenoids from ganoderma lucidum sporocarp | |
CN106317156B (en) | A kind of penta hydroxy group diones cucurbit alkane type triterpenoid and its preparation method and purposes | |
CN107446014B (en) | Dulong Paris polyphylla ethanol extract and its application in pharmacy separate and identification method with its chemical component | |
CN103720740A (en) | Gynostemma pentaphylla extract and fungus transformation preparation method thereof | |
CN104844675A (en) | Ganoderma leucocontextum triterpenoid, medicinal composition and application thereof | |
Jin et al. | Biotransformation of ginsenosides (ginseng saponins) | |
CN103006741B (en) | Extract of anti-tumor effective components of Tinglizi and its preparation method and application | |
CN102416025B (en) | Flammulina velutipes antineoplastic active ingredient extract and its preparation method and use | |
CN102028722B (en) | Extract of effective parts of total saponins in pterocephalus hookeri as well as preparation method and application thereof | |
CN104910172B (en) | Five kinds of talan trimer preparation methods and its application | |
CN109468359B (en) | Ginsenoside Rk6Preparation method of (1) | |
Cho et al. | Three new ginsenosides from the heat-processed roots of Panax ginseng | |
CN103027932A (en) | Cortex periplocae anti-tumor effective component extractive as well as preparation method and application thereof | |
CN102670935B (en) | A method for extracting total saponins from scallions | |
CN102764320A (en) | Psychotria sp. extract, and preparation method and antineoplastic application thereof | |
CN107513084A (en) | White crane rattan alkali and its extracting method and application thereof | |
CN103509077B (en) | Triterpene saponin componds and its production and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140416 |